Dr. Matthew Alfred Gubens, MD

Dr. Gubens practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Gubens' NPI, 1194923235, was assigned on July 10, 2007. Dr. Gubens graduated from Stanford University School Of Medicine in 2005. Dr. Gubens holds California license A98645.

Dr. Gubens' primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Gubens' primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. Dr. Gubens is also affiliated with UCSF Health Stanyan Hospital. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Gubens to 1 more hospital, 3 medical groups and 2 group practices and clinics, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gubens practices, 5 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Gubens' primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Gubens is board certified in medical oncology by the American Board of Internal Medicine. Dr. Gubens is licensed in California.

Dmand AI lists colorectal cancer, lung cancer, prostate cancer and purpura and thrombocytopenia among the conditions Dr. Gubens treats.

CMS data shows 1,297 Medicare services from Dr. Gubens across 7 procedure codes in 2024, for 218 Medicare patients. Medicare paid $85,847 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 218 Medicare patients who saw Dr. Gubens in 2024. The largest group is 75 to 84, with 98 patients. 75% of them have cancer, and 69% have high cholesterol. 22% are also on Medicaid. Their average risk score is 2.26, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Gubens' median patient age at 73, with 56% women.

In 2024, Dr. Gubens wrote 284 Medicare Part D claims for 63 patients. 54% of them were for generic drugs. CMS names the drug for 189 of them, across 9 drugs with 11 or more claims each, at $1,450,569 in total drug cost. In 2023, CMS named 209 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Dr. Gubens for performance year 2024, reported as part of a group. Dr. Gubens accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Gubens as offering telehealth.

Dmand AI links 43 papers to Dr. Gubens, published from 2010 to 2025. 2024 was the busiest year, with 5. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antibodies, Monoclonal, Humanized. Dr. Gubens has published most often in J Thorac Oncol. Dr. Gubens' most frequent co-authors are Collin M. Blakely, MD, Jonathan Wesley Riess, MD, MS and Trever Bivona, MD, PhD.

Dmand AI links Dr. Gubens to 3 clinical trials, 2 of them phase 2 studies. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Adenocarcinoma of Lung.

CMS Open Payments shows 274 general payments to Dr. Gubens from 21 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. AstraZeneca Pharmaceuticals LP paid the most, $80,303. It also lists 8 research payments totaling $989 in 2016.

Dmand AI lists 1 award for Dr. Gubens, most recently CMS Stage 1 EHR in 2013.

Dr. Gubens graduated from Stanford University School Of Medicine in 2005. Dr. Gubens is a member of ACP and ASCO.

Dr. Gubens is in network with 10 carriers, including Aetna, United Healthcare and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 7. Check the plan with the practice before a visit.